(CIDRAP News) The US Food and Drug Administration recently released separate documents outlining the kinds of clinical data required for licensing of new seasonal and pandemic influenza vaccines.
In a May 31 news release, the agency said the guidance documents were designed to facilitate the rapid development and approval of new vaccines by outlining the regulatory pathways for companies.